The Final Chapter for MedMen: From Cannabis Pioneer to Liquidation

MedMen Enterprises enters final wind-down with over $560M in debt. Its shares trade on the restricted Expert Market as assets are liquidated, ending any hope for shareholder recovery.

Once hailed as the poster child of the American cannabis boom, MedMen Enterprises Inc. now represents its most dramatic collapse. The company's story is nearing its conclusion not through a market revival, but through a court-supervised administrative wind-down, leaving its equity as little more than a speculative remnant.

A Speculative Shell on the Expert Market

The company's shares now trade exclusively on the OTC "Expert Market," a platform with severely restricted price visibility that underscores their status as high-risk securities. This relegation followed MedMen's failure to meet its reporting obligations, leading to a delisting from Canadian exchanges. The core reason for this fall is a profound financial crisis, which culminated in the initiation of bankruptcy proceedings in April 2024.

In a telling final act, the entire executive leadership team, including the chief financial officer, departed immediately prior to the formal bankruptcy filing. By that point, MedMen was already incapable of servicing its due debts.

Coordinated Dissolution of Assets

The scale of the failure is crystallized in the creditor claims, which exceed 560 million Canadian dollars. In Los Angeles, a court-appointed administrator is currently overseeing the dissolution of the company's California assets. The focus is on the orderly liquidation of its subsidiary, MM CAN USA.

While other players in the U.S. cannabis sector position themselves for potential federal reforms and a market re-rating, MedMen is absent from these future scenarios. The firm is no longer an active market participant but exists purely as an administrative case focused on disposing of residual assets.

For investors, this phase marks the end of a protracted decline. Attention now turns solely to the final outcomes of the bankruptcy process and the distribution of any remaining funds to secured creditors. A return to operational business or a recovery for common shareholders is conclusively off the table.